PR Newswire
SALT LAKE CITY, March 14, 2018
SALT LAKE CITY, March 14, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company,
announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate
overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20
th – 21st at the Westin Grand Central Hotel in New York City.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development
programs TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate,
is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy
end-points in Phase 3 testing with twice daily dosing and is currently under FDA review. LPCN 1111, a novel oral prodrug of
testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for
once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate
product candidate indicated for the prevention of recurrent preterm birth, is currently in Phase 2 testing and has been granted
orphan drug designation by the FDA. For more information, please visit www.lipocine.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-300613266.html
SOURCE Lipocine Inc.